| pubmed-article:16624831 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16624831 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:16624831 | lifeskim:mentions | umls-concept:C0175677 | lld:lifeskim |
| pubmed-article:16624831 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:16624831 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
| pubmed-article:16624831 | lifeskim:mentions | umls-concept:C0079594 | lld:lifeskim |
| pubmed-article:16624831 | lifeskim:mentions | umls-concept:C0599946 | lld:lifeskim |
| pubmed-article:16624831 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:16624831 | lifeskim:mentions | umls-concept:C0301625 | lld:lifeskim |
| pubmed-article:16624831 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:16624831 | pubmed:dateCreated | 2006-5-9 | lld:pubmed |
| pubmed-article:16624831 | pubmed:abstractText | The use of doxorubicin (DOX) as a chemotherapeutic agent is limited by cardiac injury. Iloprost, a stable synthetic analogue of prostacyclin, has previously been shown to protect against DOX-induced cardiomyocyte injury in vitro. Here, we addressed whether iloprost is cardioprotective in vivo and whether it compromises the anti-tumour efficacy of DOX. | lld:pubmed |
| pubmed-article:16624831 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16624831 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16624831 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16624831 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16624831 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16624831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16624831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16624831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16624831 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16624831 | pubmed:month | May | lld:pubmed |
| pubmed-article:16624831 | pubmed:issn | 0195-668X | lld:pubmed |
| pubmed-article:16624831 | pubmed:author | pubmed-author:RamA BAB | lld:pubmed |
| pubmed-article:16624831 | pubmed:author | pubmed-author:FitzgeraldDes... | lld:pubmed |
| pubmed-article:16624831 | pubmed:author | pubmed-author:JassalDavinde... | lld:pubmed |
| pubmed-article:16624831 | pubmed:author | pubmed-author:KayElaineE | lld:pubmed |
| pubmed-article:16624831 | pubmed:author | pubmed-author:HalpernElkan... | lld:pubmed |
| pubmed-article:16624831 | pubmed:author | pubmed-author:ScullyMichael... | lld:pubmed |
| pubmed-article:16624831 | pubmed:author | pubmed-author:AustinSandra... | lld:pubmed |
| pubmed-article:16624831 | pubmed:author | pubmed-author:McAllisterHes... | lld:pubmed |
| pubmed-article:16624831 | pubmed:author | pubmed-author:NeilanTomas... | lld:pubmed |
| pubmed-article:16624831 | pubmed:author | pubmed-author:DeflandreCath... | lld:pubmed |
| pubmed-article:16624831 | pubmed:author | pubmed-author:HarmeyJudy... | lld:pubmed |
| pubmed-article:16624831 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16624831 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:16624831 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16624831 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16624831 | pubmed:pagination | 1251-6 | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:meshHeading | pubmed-meshheading:16624831... | lld:pubmed |
| pubmed-article:16624831 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16624831 | pubmed:articleTitle | Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. | lld:pubmed |
| pubmed-article:16624831 | pubmed:affiliation | Department of Clinical Pharmacology, Institute of Biopharmaceutical Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland. tneilan@partners.org | lld:pubmed |
| pubmed-article:16624831 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16624831 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16624831 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16624831 | lld:pubmed |
